Show simple item record

dc.contributor.authorShadi Asadollahi
dc.contributor.authorKamran Heidari
dc.contributor.authorHamidreza Hatamabadi
dc.contributor.authorReza Vafaee
dc.contributor.authorReza Vafaee
dc.contributor.authorSomayeh Yunesian
dc.contributor.authorAlireza Azadbakht
dc.contributor.authorLadan Mirmohseni
dc.date.accessioned2017-09-18T10:49:10Z
dc.date.available2017-09-18T10:49:10Z
dc.date.issued2015-04-14
dc.identifier.issn14735857
dc.identifier.urihttp://dsp.sbmu.ac.ir/xmlui/handle/123456789/67139
dc.description.abstractCopyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. The objective of this study was to compare the efficacy of valproate versus haloperidol in decreasing the agitation level in affected patients in the emergency department. We assigned 80 acutely agitated patients to receive either intravenous sodium valproate (20 mg/kg) or intramuscular haloperidol (5 mg/1 ml). Agitation was measured at baseline and 30 min after the first injection using the Agitation-Calmness Evaluation Scale (ACES), the Positive and Negative Syndrome Scale-Excited Component subscale, and the Agitated Behavior Scale. For 80 patients treated with sodium valproate, the mean ± SD dosage was 1541.5 ± 286 mg (range 940-2400). The mean postintervention ACES scores from baseline to 30 min after drug injection were 4.73 (SD=1.93) for the valproate group and 5.45 (SD=2.09) for the haloperidol group (P=0.028). No significant differences were observed in terms of the mean changes 30 min after the intervention for two additional agitation scales. A larger proportion of patients in the haloperidol group experienced intense sedation (36.2%, P < 0.001) and extrapyramidal symptoms (8.7%, P=0.007) compared with the valproate group (2.5% for intense sedation, no patient for extrapyramidal symptoms). The findings suggest that in the clinical practice setting of emergency psychiatry, intravenous valproate is as effective as haloperidol in reducing agitation, with a better safety profile.
dc.sourceInternational Clinical Psychopharmacology
dc.subjectAgitation
dc.subjectHaloperidol
dc.subjectPsychotherapy
dc.subjectRandomized-controlled trial
dc.subjectTherapeutics
dc.subjectValproic acid
dc.titleEfficacy and safety of valproic acid versus haloperidol in patients with acute agitation: Results of a randomized, double-blind, parallel-group trial
dc.journal.volume30
dc.journal.issue3
dc.identifier.doi10.1097/YIC.0000000000000064
dc.journal.pages142-150
dc.contributor.authorid55533473800
dc.contributor.authorid26430683100
dc.contributor.authorid43661560900
dc.contributor.authorid46161657000
dc.contributor.authorid46161657000
dc.contributor.authorid14622058700
dc.contributor.authorid56450927500
dc.contributor.authorid56451073900
dc.contributor.citation55533473800|60018934|Shadi Asadollahi
dc.contributor.citation26430683100|60018934|Kamran Heidari
dc.contributor.citation43661560900|60018934|Hamidreza Hatamabadi
dc.contributor.citation46161657000|60018934|Reza Vafaee
dc.contributor.citation46161657000|60018934|Reza Vafaee
dc.contributor.citation14622058700|60018934|Somayeh Yunesian
dc.contributor.citation56450927500|60018934|Alireza Azadbakht
dc.contributor.citation56451073900|60018934|Ladan Mirmohseni
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record